LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

LLY

1,008.9

-0.06%↓

JNJ

229.95

+0.24%↑

ABBV

212.11

-1.29%↓

UNH

384.82

-2.5%↓

AZN

187.27

+0.74%↑

Home・Akcijų sąrašas・Design Therapeutics Inc

Design Therapeutics Inc

Uždarymo kaina

11.05 9.73

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.26

Max

10.86

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.6M -18M
Pelnas, tenkantis vienai akcijai	-0.29
Darbuotojai	54
EBITDA	-1.5M -20M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+71.96% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	98M 898M
Ankstesnė atidarymo kaina	1.32
Ankstesnė uždarymo kaina	11.05

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

3.26 / 3.63 Palaikymas ir pasipriešinimas

Design Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-19 20:36; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

2026-05-19 23:47; UTC

Rinkos pokalbiai

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

2026-05-19 23:34; UTC

Rinkos pokalbiai

Gold Edges Higher on Possible Technical Recovery -- Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 23:28; UTC

Rinkos pokalbiai

Uždarbis

F&P Healthcare's Outlook Key for Investors -- Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-19 23:10; UTC

Rinkos pokalbiai

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

2026-05-19 22:02; UTC

Uždarbis

ZTO Express (Cayman): Di Xu to Resign From Board

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

2026-05-19 22:01; UTC

Uždarbis

ZTO Express (Cayman) 1Q EPS 39c >ZTO

2026-05-19 22:00; UTC

Uždarbis

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

2026-05-19 21:37; UTC

Uždarbis

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

2026-05-19 21:31; UTC

Įsigijimai, susijungimai, perėmimai

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

2026-05-19 21:01; UTC

Uždarbis

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

2026-05-19 20:58; UTC

Uždarbis

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

2026-05-19 20:46; UTC

Karštos akcijos

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

2026-05-19 20:43; UTC

Rinkos pokalbiai

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

2026-05-19 20:34; UTC

Uždarbis

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q EPS 5c >JHX

2026-05-19 20:32; UTC

Uždarbis

James Hardie Industries 4Q Sales $1.4B >JHX

2026-05-19 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Buy Empower Semiconductor for $1.5B

2026-05-19 20:18; UTC

Rinkos pokalbiai

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-19 20:13; UTC

Rinkos pokalbiai

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

2026-05-19 20:03; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

2026-05-19 20:02; UTC

Įsigijimai, susijungimai, perėmimai

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

2026-05-19 19:23; UTC

Rinkos pokalbiai

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Akcijų palyginimas

Kainos pokytis

Design Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

71.96% į viršų

12 mėnesių prognozė

Vidutinis 18.4 USD 71.96%

Aukščiausias 22 USD

Žemiausias 14 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Design Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Design Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.26 / 3.63Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Design Therapeutics Inc

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.